In advance of November 10, 2026 GDUFA goal date, three commercial lots of Preservative-Free Ketamine have been successfully ...
4d
NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine
In advance of November 10, 2026, GDUFA goal date, all requested changes were classified as “MINOR.”NRx was requested to ...
NRx Pharmaceuticals Inc. ( NRXP) announced Thursday that it has received a Discipline Review Letter from the U.S. Food and Drug Administration (FDA) requesting minor changes to the labeling of its ...
Good morning, everyone, and welcome to the NRx Pharmaceuticals, Inc. Corporate Update Call. [Operator Instructions] As a reminder, this conference call is being recorded. I will now turn the call over ...
Patent expected to be Orange Book listable, if granted NRX-100, preservative free, IV ketamine, is designed to avoid potential toxicity concerns linked to benzethonium chloride, used in currently ...
NRx Pharmaceuticals Inc. (NASDAQ: NRXP) has initiated commercial manufacturing for its preservative-free ketamine product following guidance from the FDA Office of Generic Drugs, according to a ...
NRx Pharmaceuticals Inc. (NASDAQ: NRXP) announced it has re-filed an Abbreviated New Drug Application with the FDA for KETAFREE, a preservative-free intravenous ketamine formulation. The filing ...
NRx has filed an Abbreviated New Drug Application (ANDA), and initiated a New Drug Application filing for NRX-100 with an application for the Commissioner's National Priority Voucher Program for the ...
Thursday, NRx Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has requested minor changes to the submitted label for NRx's Preservative-Free Ketamine pr ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results